Selecta Biosciences Reports Net Loss of $33.05 Million for the First Half of 2023

Selecta Biosciences, Inc. (SELB), a biotechnology company speciali zing in immune tolerance therapies, has announced its financial results for the first half of 2023. The company reported a net loss of $33.05 million during this period. Additionally, collaboration and license revenue for the first six months of the year totaled $11.19 million.

Consolidated Balance Sheets

The company's consolidated balance sheets as of June 30, 2023, and December 31, 2022, reveal that Selecta Biosciences' total assets amounted to $139.51 million as of the end of June, a decrease from $165.89 million in assets at the close of 2022. The decrease in assets was attributed to changes in cash, cash equivalents, marketable securities, and other current assets.

Consolidated Statements of Operations and Comprehensive Income (Loss)